Sex-specific differences in cardiac maladaptation to hypertension and arterial stiffening

Nicholas Cauwenberghs, Tatiana Kuznetsova1

  • 1Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium. tatiana.kouznetsova@med.kuleuven.be.

Kardiologia Polska
|August 10, 2018
PubMed

Insights

Heart failure (HF) affects men and women similarly, but women are more prone to HF with preserved ejection fraction. Hypertension and arterial stiffness are key risk factors contributing to these sex differences in cardiac conditions.

Area of Science:

  • Cardiology
  • Cardiovascular Disease
  • Hypertension Research

Background:

  • Symptomatic heart failure (HF) prevalence is comparable between sexes, representing a significant portion of initial cardiovascular disease diagnoses.
  • A notable sex-based divergence exists in HF subtypes: men more commonly present with HF with reduced ejection fraction, while women disproportionately develop HF with preserved ejection fraction.

Purpose of the Study:

  • To review current epidemiological data on sex-based disparities in cardiac maladaptation.
  • To explore the differing manifestations of heart failure (HF) in men and women.
  • To examine the roles of hypertension and arterial stiffness in sex-specific HF development.

Main Methods:

  • Literature review of epidemiological studies.
  • Analysis of sex differences in heart failure prevalence and subtypes.
  • Examination of the impact of hypertension and arterial stiffness on cardiac structure and function.

Main Results:

  • Overall prevalence of symptomatic heart failure (HF) is similar in men and women.
  • Women exhibit a higher frequency of HF with preserved ejection fraction compared to men.
  • Men are more frequently diagnosed with HF with reduced ejection fraction.
  • High blood pressure and arterial stiffness are identified as major risk factors for HF in both sexes.

Conclusions:

  • Significant sex discrepancies exist in the type of heart failure (HF) developed, despite similar overall prevalence.
  • Hypertension and arterial stiffness contribute to sex-specific cardiac maladaptations leading to HF.
  • Further research into sex-specific mechanisms is crucial for targeted prevention and treatment strategies for heart failure.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
109.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550